WHAT IS CLAIMED IS:

1. Use of a protein kinase C theta (PKC-θ) inhibitor and at least one cancer therapy agent in the manufacture of a medicament for treating or preventing a metastatic cancer, wherein the metastatic cancer comprises a cancer stem cell (CSC) and a non-CSC tumor cell, wherein the PKC-θ inhibitor inhibits at least one of: formation, proliferation, or maintenance of the CSC; and/or inhibits epithelial-to-mesenchymal transition (EMT) of the CSC; and/or stimulates or induces mesenchymal-to-epithelial transition (MET) of the CSC, and wherein the cancer therapy agent inhibits proliferation, survival or viability of the non-CSC tumor cell.

2. The use according to claim 1, wherein the PKC-θ inhibitor is a selective PKC-θ inhibitor.

3. The use according to claim 1, wherein the PKC-θ inhibitor is a non-selective PKC-θ inhibitor .

4. The use according to any one of claims 1 to 3, wherein the cancer therapy agent is selected from a radiosensitizing agent, a chemotherapeutic agent, a hormone ablation therapy agent, and an immunotherapeutic agent

5. The use according to claim 4, wherein the cancer therapy agent is an antibody.

6. The use according to any one of claims 1 to 5, wherein the cancer is selected from breast, prostate, lung, bladder, pancreatic, colon, melanoma, liver or glioma cancer.

7. The use according to any one of claims 1 to 5, wherein the cancer is breast cancer.